Loading news...
Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
– Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 –
Esperion Therapeutics, Inc. (NASDAQ: ESPR - Get Free Report) gapped up before the market opened on Friday. The stock had previously closed at $3.70, but opened at $3.86. Esperion Therapeutics shares last traded at $3.8350, with a volume of 519,721 shares traded. Analyst Ratings Changes Several equities research analysts have weighed in on ESPR shares.
Esperion Therapeutics, Inc. (NASDAQ: ESPR - Get Free Report) was the target of some unusual options trading on Monday. Stock traders bought 10,363 call options on the company. This is an increase of 221% compared to the average daily volume of 3,229 call options. Analyst Ratings Changes A number of equities research analysts have issued reports
ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on December 4, 2025, the Company granted three new employees (i) non-qualified stock options to purchase an aggregate of 380,000 shares of common stock, all of which were granted to John Harlow, the Company's newly appointed Chief Commercial Officer, and (ii) 435,536 restricted stock units (RSUs), 424,536 of which were awarded to Mr. Harlow, under Esperion's 2017 Inducement Equity Incentive Plan.
Esperion Therapeutics, Inc. (NASDAQ: ESPR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have issued a buy recommendation and one has assigned
Esperion Therapeutics, Inc. ( ESPR ) Jefferies London Healthcare Conference 2025 November 18, 2025 3:00 AM EST Company Participants Benjamin Halladay - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Good morning. Welcome to the Jefferies London Healthcare Conference.
ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company's partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for NILEMDO is expected in Q2 2026.
Esperion Therapeutics, Inc. and C4 Therapeutics, Inc. were among the top contributors to performance. SiTime Corp. was also a top contributor. The company provides silicon timing chips for a wide range of electronics. The greatest detractor from Fund performance for the quarter was Monday.com Ltd.
Esperion Therapeutics, Inc. ( ESPR ) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health November 11, 2025 2:00 PM EST Company Participants Sheldon Koenig - President, CEO & Director LeAnne Bloedon Conference Call Participants Dharmesh Patel Fatima Rodriguez Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Jason Zemansky - BofA Securities, Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division Presentation Operator Good day, everyone.
Esperion Therapeutics remains a buy despite market skepticism, recent stock offering, and underwhelming Q3 earnings, supported by strong cardiovascular drug franchises. ESPR's profitability timeline is intact, but execution is critical; Q4 results are a key 'prove it' moment as the company targets sustained profitability and margin improvements. Valuation is attractive with double-digit revenue growth, reasonable price/sales ratios, and upcoming milestone payments and royalties from global partnerships, especially in Japan and Europe.
Esperion's Q3 loss widens despite a 69% jump in revenues. Mixed results and investor jitters probably drag ESPR shares down 15%.
ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 4, 2025, the Company granted 23 new employees 77,650 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.
Esperion Therapeutics, Inc. ( ESPR ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Alina Venezia Sheldon Koenig - President, CEO & Director Benjamin Halladay - Chief Financial Officer Lisa Schafer Conference Call Participants Georgia Bank - Jefferies LLC, Research Division Jason Zemansky - BofA Securities, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Serge Belanger - Needham & Company, LLC, Research Division Sara Nik - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Hello, ladies and gentlemen, and thank you for standing by.
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.15 per share a year ago.
– Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance –
ANN ARBOR, Mich., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that an oral presentation and a poster presentation have been accepted for presentation at the AHA Scientific Sessions 2025 in New Orleans, LA, November 7-10, 2025.
Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.
Esperion's stock sinks after pricing its common stock offering at $2.50 per share, a 19% discount to the prior close.
ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C), today announced the pricing of an underwritten public offering of 30,000,000 shares of its common stock at a public offering price of $2.50 per share. In addition, Esperion has granted the underwriters a 30-day option to purchase up to an additional 4,500,000 shares of its common stock. The gross proceeds to Esperion from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $75.0 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares of common stock in the offering are to be sold by Esperion. The offering is expected to close on or about October 9, 2025, subject to satisfaction of customary closing conditions.